Concepts (201)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alopecia | 8 | 2022 | 45 | 3.450 |
Why?
|
| Skin Neoplasms | 14 | 2022 | 375 | 2.860 |
Why?
|
| Melanoma | 6 | 2022 | 335 | 1.950 |
Why?
|
| Hair Follicle | 6 | 2022 | 37 | 1.570 |
Why?
|
| Facial Dermatoses | 2 | 2017 | 14 | 1.240 |
Why?
|
| Scalp | 4 | 2020 | 47 | 1.190 |
Why?
|
| Nevus, Pigmented | 4 | 2022 | 30 | 1.110 |
Why?
|
| Inflammation | 4 | 2021 | 1030 | 1.070 |
Why?
|
| Cytokines | 2 | 2020 | 866 | 1.040 |
Why?
|
| Eosinophils | 2 | 2022 | 60 | 1.000 |
Why?
|
| Nevus, Epithelioid and Spindle Cell | 3 | 2022 | 11 | 0.980 |
Why?
|
| Epidermis | 2 | 2020 | 42 | 0.890 |
Why?
|
| Hemangioma | 2 | 2020 | 51 | 0.880 |
Why?
|
| Traction | 1 | 2022 | 10 | 0.870 |
Why?
|
| Neurocutaneous Syndromes | 1 | 2020 | 7 | 0.760 |
Why?
|
| Dermoscopy | 2 | 2018 | 14 | 0.760 |
Why?
|
| Chemokine CCL26 | 1 | 2019 | 1 | 0.720 |
Why?
|
| Chemokine CCL24 | 1 | 2019 | 1 | 0.720 |
Why?
|
| Chemokine CCL11 | 1 | 2019 | 9 | 0.720 |
Why?
|
| Cytoplasm | 2 | 2017 | 155 | 0.710 |
Why?
|
| Eosinophilia | 1 | 2019 | 47 | 0.690 |
Why?
|
| Dermatitis | 1 | 2019 | 28 | 0.680 |
Why?
|
| Cell Nucleus | 2 | 2017 | 305 | 0.670 |
Why?
|
| Nevus | 1 | 2017 | 17 | 0.630 |
Why?
|
| Insurance Carriers | 1 | 2017 | 9 | 0.630 |
Why?
|
| Skin Diseases, Vesiculobullous | 1 | 2017 | 14 | 0.630 |
Why?
|
| Laser Therapy | 1 | 2017 | 54 | 0.620 |
Why?
|
| Vascular Malformations | 1 | 2017 | 19 | 0.620 |
Why?
|
| Aminoquinolines | 1 | 2017 | 14 | 0.610 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2017 | 52 | 0.610 |
Why?
|
| Hand Dermatoses | 1 | 2016 | 10 | 0.590 |
Why?
|
| Keratosis | 1 | 2016 | 17 | 0.590 |
Why?
|
| Foot Dermatoses | 1 | 2016 | 12 | 0.590 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2020 | 689 | 0.590 |
Why?
|
| Autoimmune Diseases | 1 | 2017 | 186 | 0.560 |
Why?
|
| Humans | 41 | 2022 | 68525 | 0.540 |
Why?
|
| Fibrosis | 4 | 2020 | 371 | 0.510 |
Why?
|
| Carcinoma in Situ | 3 | 2017 | 45 | 0.440 |
Why?
|
| Diagnosis, Differential | 7 | 2022 | 1139 | 0.400 |
Why?
|
| Skin | 4 | 2018 | 451 | 0.390 |
Why?
|
| Antineoplastic Agents | 2 | 2018 | 1070 | 0.370 |
Why?
|
| Cicatrix | 2 | 2022 | 60 | 0.370 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2020 | 624 | 0.340 |
Why?
|
| Keratinocytes | 2 | 2019 | 68 | 0.330 |
Why?
|
| Immunohistochemistry | 3 | 2020 | 1174 | 0.320 |
Why?
|
| Biomarkers, Tumor | 4 | 2020 | 508 | 0.320 |
Why?
|
| Sweat Glands | 2 | 2016 | 10 | 0.290 |
Why?
|
| Neoplasms, Multiple Primary | 2 | 2017 | 46 | 0.290 |
Why?
|
| Skin Diseases | 2 | 2019 | 122 | 0.280 |
Why?
|
| Retrospective Studies | 8 | 2020 | 7264 | 0.280 |
Why?
|
| Melanocytes | 3 | 2020 | 23 | 0.280 |
Why?
|
| Hair | 2 | 2020 | 46 | 0.230 |
Why?
|
| Syndrome | 2 | 2020 | 255 | 0.230 |
Why?
|
| Microscopy, Fluorescence, Multiphoton | 2 | 2020 | 27 | 0.230 |
Why?
|
| Female | 14 | 2022 | 38015 | 0.210 |
Why?
|
| Pemphigus | 2 | 2018 | 12 | 0.200 |
Why?
|
| Biopsy | 6 | 2020 | 539 | 0.200 |
Why?
|
| Oncogenes | 1 | 2022 | 71 | 0.200 |
Why?
|
| Platelet-Rich Plasma | 1 | 2020 | 6 | 0.200 |
Why?
|
| Myosin Type V | 1 | 2020 | 1 | 0.190 |
Why?
|
| Biological Factors | 1 | 2020 | 11 | 0.190 |
Why?
|
| Receptor, trkC | 1 | 2020 | 6 | 0.190 |
Why?
|
| Gene Fusion | 1 | 2020 | 4 | 0.190 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2020 | 18 | 0.190 |
Why?
|
| Forehead | 2 | 2017 | 13 | 0.190 |
Why?
|
| Alopecia Areata | 1 | 2020 | 17 | 0.190 |
Why?
|
| Phimosis | 1 | 2020 | 2 | 0.190 |
Why?
|
| Myosin Heavy Chains | 1 | 2020 | 49 | 0.190 |
Why?
|
| Skin Abnormalities | 1 | 2020 | 11 | 0.190 |
Why?
|
| Angiokeratoma | 1 | 2020 | 1 | 0.190 |
Why?
|
| Education, Medical | 1 | 2022 | 147 | 0.190 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2022 | 148 | 0.190 |
Why?
|
| Tomography, Optical Coherence | 1 | 2020 | 88 | 0.190 |
Why?
|
| Immunotherapy | 1 | 2022 | 212 | 0.180 |
Why?
|
| Paraffin Embedding | 1 | 2020 | 47 | 0.180 |
Why?
|
| Epidermolysis Bullosa Acquisita | 1 | 2019 | 1 | 0.180 |
Why?
|
| Joint Instability | 1 | 2020 | 87 | 0.170 |
Why?
|
| Workflow | 1 | 2020 | 100 | 0.170 |
Why?
|
| Autoantibodies | 2 | 2018 | 434 | 0.170 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2018 | 15 | 0.170 |
Why?
|
| Pemphigus, Benign Familial | 1 | 2018 | 4 | 0.170 |
Why?
|
| Regional Blood Flow | 1 | 2018 | 168 | 0.160 |
Why?
|
| Histiocytosis, Non-Langerhans-Cell | 1 | 2018 | 5 | 0.160 |
Why?
|
| Male | 13 | 2020 | 37281 | 0.160 |
Why?
|
| Middle Aged | 8 | 2020 | 21119 | 0.160 |
Why?
|
| Leg Dermatoses | 1 | 2018 | 6 | 0.160 |
Why?
|
| Intense Pulsed Light Therapy | 1 | 2017 | 1 | 0.160 |
Why?
|
| Low-Level Light Therapy | 1 | 2017 | 4 | 0.160 |
Why?
|
| Angiofibroma | 1 | 2017 | 4 | 0.160 |
Why?
|
| Lymphatic Abnormalities | 1 | 2017 | 2 | 0.160 |
Why?
|
| Granuloma, Pyogenic | 1 | 2017 | 5 | 0.160 |
Why?
|
| Rosacea | 1 | 2017 | 5 | 0.160 |
Why?
|
| Epithelioid Cells | 1 | 2017 | 3 | 0.160 |
Why?
|
| Port-Wine Stain | 1 | 2017 | 7 | 0.160 |
Why?
|
| Pemphigoid, Bullous | 1 | 2018 | 13 | 0.160 |
Why?
|
| Hemangioma, Capillary | 1 | 2017 | 6 | 0.160 |
Why?
|
| Epitopes | 1 | 2018 | 146 | 0.160 |
Why?
|
| Microscopy, Confocal | 1 | 2018 | 337 | 0.160 |
Why?
|
| Paget Disease, Extramammary | 1 | 2017 | 5 | 0.150 |
Why?
|
| Paget's Disease, Mammary | 1 | 2017 | 4 | 0.150 |
Why?
|
| Neurilemmoma | 1 | 2017 | 26 | 0.150 |
Why?
|
| Bowen's Disease | 1 | 2017 | 6 | 0.150 |
Why?
|
| Hypopigmentation | 1 | 2017 | 12 | 0.150 |
Why?
|
| Scalp Dermatoses | 1 | 2017 | 13 | 0.150 |
Why?
|
| Photochemotherapy | 1 | 2017 | 59 | 0.150 |
Why?
|
| Lichen Planus | 1 | 2017 | 17 | 0.150 |
Why?
|
| Hyperplasia | 1 | 2017 | 89 | 0.150 |
Why?
|
| Erythema | 1 | 2017 | 18 | 0.150 |
Why?
|
| Hyperpigmentation | 1 | 2017 | 7 | 0.150 |
Why?
|
| Adenocarcinoma, Sebaceous | 1 | 2016 | 2 | 0.150 |
Why?
|
| Nevus, Sebaceous of Jadassohn | 1 | 2016 | 2 | 0.150 |
Why?
|
| Immunologic Factors | 1 | 2017 | 87 | 0.150 |
Why?
|
| Software | 1 | 2020 | 418 | 0.150 |
Why?
|
| Sebaceous Gland Neoplasms | 1 | 2016 | 4 | 0.150 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2018 | 151 | 0.150 |
Why?
|
| Cell Nucleolus | 1 | 2016 | 14 | 0.150 |
Why?
|
| Sweat Gland Neoplasms | 1 | 2016 | 16 | 0.150 |
Why?
|
| Microscopy, Polarization | 1 | 2016 | 7 | 0.150 |
Why?
|
| Tinea | 1 | 2016 | 6 | 0.140 |
Why?
|
| Urogenital Neoplasms | 1 | 2016 | 9 | 0.140 |
Why?
|
| Sebaceous Glands | 1 | 2016 | 8 | 0.140 |
Why?
|
| Anus Neoplasms | 1 | 2016 | 13 | 0.140 |
Why?
|
| Lupus Erythematosus, Cutaneous | 1 | 2016 | 7 | 0.140 |
Why?
|
| Staining and Labeling | 1 | 2016 | 144 | 0.140 |
Why?
|
| Mitosis | 1 | 2016 | 76 | 0.140 |
Why?
|
| Fibrillar Collagens | 1 | 2016 | 49 | 0.140 |
Why?
|
| Chromatin | 1 | 2016 | 76 | 0.140 |
Why?
|
| Biomarkers | 1 | 2022 | 1593 | 0.140 |
Why?
|
| Precancerous Conditions | 1 | 2016 | 74 | 0.140 |
Why?
|
| Immunoglobulin M | 1 | 2016 | 172 | 0.130 |
Why?
|
| Sensitivity and Specificity | 2 | 2016 | 1753 | 0.130 |
Why?
|
| Aged, 80 and over | 3 | 2020 | 4843 | 0.120 |
Why?
|
| Child | 2 | 2022 | 6400 | 0.120 |
Why?
|
| Infant | 1 | 2020 | 2891 | 0.120 |
Why?
|
| Models, Theoretical | 1 | 2016 | 384 | 0.120 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 1046 | 0.120 |
Why?
|
| Cell Differentiation | 1 | 2016 | 1034 | 0.110 |
Why?
|
| Neoplasms | 2 | 2020 | 1660 | 0.100 |
Why?
|
| Aged | 4 | 2020 | 14842 | 0.100 |
Why?
|
| Head and Neck Neoplasms | 1 | 2016 | 561 | 0.100 |
Why?
|
| Adult | 4 | 2020 | 21375 | 0.090 |
Why?
|
| Breast Neoplasms | 1 | 2017 | 1533 | 0.080 |
Why?
|
| Pilot Projects | 2 | 2022 | 1341 | 0.070 |
Why?
|
| United States | 1 | 2017 | 7335 | 0.060 |
Why?
|
| Young Adult | 3 | 2020 | 5708 | 0.060 |
Why?
|
| Predictive Value of Tests | 2 | 2017 | 1465 | 0.060 |
Why?
|
| Schools, Medical | 1 | 2022 | 157 | 0.050 |
Why?
|
| Cell Shape | 1 | 2020 | 37 | 0.050 |
Why?
|
| Thorax | 1 | 2020 | 49 | 0.050 |
Why?
|
| Artificial Intelligence | 1 | 2022 | 159 | 0.050 |
Why?
|
| Cell Size | 1 | 2020 | 76 | 0.050 |
Why?
|
| Immunity | 1 | 2020 | 67 | 0.050 |
Why?
|
| Foot | 1 | 2020 | 66 | 0.040 |
Why?
|
| Health Education | 1 | 2022 | 279 | 0.040 |
Why?
|
| Leg | 1 | 2020 | 191 | 0.040 |
Why?
|
| Desmoglein 3 | 1 | 2018 | 2 | 0.040 |
Why?
|
| Desmosomes | 1 | 2018 | 14 | 0.040 |
Why?
|
| Clobetasol | 1 | 2018 | 1 | 0.040 |
Why?
|
| Autoantigens | 1 | 2018 | 91 | 0.040 |
Why?
|
| Physical Examination | 1 | 2018 | 152 | 0.040 |
Why?
|
| Curriculum | 1 | 2022 | 575 | 0.040 |
Why?
|
| Administration, Topical | 1 | 2018 | 111 | 0.040 |
Why?
|
| Asymptomatic Diseases | 1 | 2017 | 43 | 0.040 |
Why?
|
| Prednisone | 1 | 2018 | 104 | 0.040 |
Why?
|
| Phantoms, Imaging | 1 | 2018 | 189 | 0.040 |
Why?
|
| Chin | 1 | 2017 | 5 | 0.040 |
Why?
|
| Phenotype | 1 | 2020 | 946 | 0.040 |
Why?
|
| Lymphatic Metastasis | 1 | 2018 | 274 | 0.040 |
Why?
|
| Cell Count | 1 | 2017 | 248 | 0.040 |
Why?
|
| Face | 1 | 2017 | 46 | 0.040 |
Why?
|
| Clinical Competence | 1 | 2022 | 657 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2020 | 785 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2018 | 411 | 0.040 |
Why?
|
| Neck | 1 | 2017 | 62 | 0.040 |
Why?
|
| Lichen Sclerosus et Atrophicus | 1 | 2016 | 3 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2018 | 306 | 0.040 |
Why?
|
| Periodic Acid-Schiff Reaction | 1 | 2016 | 6 | 0.040 |
Why?
|
| Keloid | 1 | 2016 | 10 | 0.040 |
Why?
|
| Dermatofibrosarcoma | 1 | 2016 | 8 | 0.040 |
Why?
|
| Histiocytoma, Benign Fibrous | 1 | 2016 | 10 | 0.040 |
Why?
|
| Scleroderma, Localized | 1 | 2016 | 19 | 0.040 |
Why?
|
| Fluorescent Antibody Technique, Direct | 1 | 2016 | 21 | 0.040 |
Why?
|
| Cell Line | 1 | 2020 | 1752 | 0.040 |
Why?
|
| Analysis of Variance | 1 | 2018 | 1039 | 0.030 |
Why?
|
| Reference Values | 1 | 2017 | 579 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 648 | 0.030 |
Why?
|
| Immunoglobulin A | 1 | 2016 | 79 | 0.030 |
Why?
|
| Complement C3 | 1 | 2016 | 101 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2018 | 799 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 2016 | 481 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2020 | 3185 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2017 | 1548 | 0.030 |
Why?
|
| Algorithms | 1 | 2018 | 1194 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 2550 | 0.030 |
Why?
|
| Animals | 2 | 2019 | 20877 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2017 | 2004 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2018 | 3702 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2017 | 2264 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2017 | 3256 | 0.020 |
Why?
|
| Adolescent | 1 | 2020 | 8903 | 0.020 |
Why?
|
| Mice | 1 | 2018 | 8472 | 0.020 |
Why?
|